Klexane
Phase 3Small molecule
Klexane is one of 9 small molecule programs targeting Habitual Abortion. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Habitual Abortion
#DrugCompanyPhaseTrials
1Plaquenil
Alnylam PharmaceuticalsApproved
Folvite
Eli LillyApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Synthroid
IInstitut Jerome Lejeune
Approved
Gynorest
SSolvay Pharmaceuticals
Phase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 1
Klexane
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
Bayer Aspirin
BayerPreclinical
Femara
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Habitual Abortion1 trial
Islet Transplantation1 trial
Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00789308·24 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Klexane. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details